Isracann Biosciences Inc.
ISCNF · OTC
5/31/2022 | 5/31/2021 | 5/31/2020 | 5/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $2 | $3 | $5 | $4 |
| SG&A Expenses | $3 | $5 | $12 | $6 |
| Sales & Mktg Exp. | $0 | $2 | $7 | $2 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $5 | $12 | $6 |
| Operating Income | -$2 | -$5 | -$11 | -$6 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$2 | -$20 | -$13 | $0 |
| Pre-Tax Income | -$5 | -$25 | -$24 | -$6 |
| Tax Expense | $0 | $0 | -$0 | $0 |
| Net Income | -$5 | -$25 | -$24 | -$10 |
| % Margin | – | – | – | – |
| EPS | -0.032 | -0.18 | -0.26 | -0.75 |
| % Growth | 82.3% | 30.8% | 65.3% | – |
| EPS Diluted | -0.032 | -0.18 | -0.26 | -0.75 |
| Weighted Avg Shares Out | 148 | 139 | 93 | 13 |
| Weighted Avg Shares Out Dil | 148 | 138 | 93 | 13 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$2 | -$5 | -$11 | -$5 |
| % Margin | – | – | – | – |